We are live on ! Find out more
CTKB icon

Cytek Biosciences
CTKB

52 hedge funds and large institutions have $572M invested in Cytek Biosciences in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 9

0.51% more ownership

Funds ownership: 25.69% → 26.2% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 54 → 52 (-2)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

23% less capital invested

Capital invested by funds: $744M → $572M (-$172M)

Holders
52
Holders Change
-2
Holders Change %
-3.7%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
20
Reduced
9
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MGM
Miura Global Management
New York
+$18.9M
2
BlackRock
BlackRock
New York
+$10.8M
3
E
Ergoteles
New York
+$3.71M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.28M
5
PPA
Parametric Portfolio Associates
Washington
+$1.63M

Top Sellers

Rank Fund Capital Flow
1
RFA
Reilly Financial Advisors
California
-$10.6M
2
DCM
Driehaus Capital Management
Illinois
-$9.45M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$7.02M
4
Millennium Management
Millennium Management
New York
-$3.83M
5
CCM
CAAS Capital Management
New York
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$157M – – –
HA
2
HHLR Advisors
Cayman Islands
$143M – – –
MGM
3
Miura Global Management
New York
$49.3M +$18.9M +902,500 +43%
Fidelity International
4
Fidelity International
Bermuda
$43.5M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$43.5M – – –
BlackRock
6
BlackRock
New York
$38.7M +$10.8M +515,716 +28%
O
7
OrbiMed
New York
$31.4M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$19.8M +$322K +15,374 +1%
PVI
9
Pura Vida Investments
New York
$6.88M -$473K -22,591 -5%
OCA
10
Octagon Capital Advisors
New York
$6.53M -$2.09M -100,000 -20%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$5.79M +$713K +34,032 +11%
State Street
12
State Street
Massachusetts
$4.44M +$1.35M +64,590 +31%
E
13
Ergoteles
New York
$2.89M +$3.71M +177,001 New
Northern Trust
14
Northern Trust
Illinois
$2.61M +$334K +15,946 +11%
FAM
15
Fred Alger Management
New York
$1.78M -$81.5K -3,892 -3%
Renaissance Technologies
16
Renaissance Technologies
New York
$1.78M +$2.28M +109,000 New
Charles Schwab
17
Charles Schwab
California
$1.73M +$56.8K +2,714 +3%
Citadel Advisors
18
Citadel Advisors
Florida
$1.51M +$1.61M +77,051 +503%
PPA
19
Parametric Portfolio Associates
Washington
$1.27M +$1.63M +77,737 New
N
20
Nuveen
North Carolina
$1.23M +$961K +45,889 +199%
Walleye Capital
21
Walleye Capital
New York
$1.07M +$951K +45,420 +223%
Goldman Sachs
22
Goldman Sachs
New York
$980K -$194K -9,262 -13%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$863K +$299K +14,290 +37%
Norges Bank
24
Norges Bank
Norway
$546K -$585K -27,947 -46%
PL
25
Parkwood LLC
Ohio
$528K +$677K +32,327 New
1
2 3

CTKB Hedge Fund Activity: Q4 2021 in Review

52 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q4 2021, worth a combined $572M — down 23% from $744M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CTKB and 11 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 20 added.

The largest buyer was Miura Global Management, adding an estimated $18.9M. The largest seller was Reilly Financial Advisors, exiting entirely with an estimated $10.6M sold.

  • 52 institutional investors held Cytek Biosciences (CTKB) as of Q4 2021, down from 54 in Q3 2021.
  • Funds reported $572M of Cytek Biosciences stock for Q4 2021, down 23% quarter-over-quarter.
  • 11 funds opened new Cytek Biosciences positions in Q4 2021 and 13 closed out, a net change of -2 holders.
  • The largest Cytek Biosciences buyer in Q4 2021 was Miura Global Management, an estimated $18.9M added.
  • The largest Cytek Biosciences seller in Q4 2021 was Reilly Financial Advisors, an estimated $10.6M sold.

Based on aggregated 13F filings for Q4 2021.